Comparative Protective Effects of ATP and TPP Against Olaparib-Induced Ovarian Injury in Rats: Insights from Biochemical Parameters, Histopathology, and IRE1α, Cleaved Caspase-3, LC3B, and NF-κB p65 Double Immunofluorescence
Özet
Background: Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor used to treat several malignancies. Previous studies have reported that olaparib may induce ovarian injury by elevating reactive oxygen species and impairing cellular energy homeostasis. ATP is a central regulator of intracellular energy balance and antioxidant defense, whereas thiamine pyrophosphate (TPP), the active form of vitamin B1, supports ATP biosynthesis and possesses antioxidant and anti-inflammatory properties. This study compared the protective effects of ATP and TPP against olaparib-induced ovarian injury in rats. Methods: Twenty-four female Wistar albino rats were randomly assigned to four groups (n=6 each): healthy control (HG), olaparib-only (OLP), ATP plus olaparib (ATOL), and TPP plus olaparib (TPOL). Olaparib (100 mg/kg, orally, twice daily), ATP (5 mg/kg, intraperitoneally, once daily), and TPP (25 mg/kg, intraperitoneally, once daily) were administered for 14 consecutive days. Ovarian tissue levels of oxidant (MDA), antioxidants (tGSH, SOD, CAT), and pro-inflammatory cytokine (IL-6) were determined. Tissue specimens underwent histopathological (follicular and parenchymal degeneration) and double immunofluorescence analyses (IRE1α, cleaved Caspase-3, LC3B, and NF-κB p65 immunopositivity). Results: Olaparib significantly increased oxidant and pro-inflammatory cytokine levels and decreased antioxidant levels. Histopathology revealed severe follicular and parenchymal degeneration, and immunofluorescence analysis showed significantly increased IRE1α, cleaved Caspase-3, LC3B, and NF-κB p65 immunopositivity. Both ATP and TPP pre-treatment significantly attenuated olaparib-induced oxidative stress, inflammatory responses, histopathological injury, and cellular stress marker immunopositivity. ATP demonstrated a more pronounced protective effect than TPP, particularly regarding follicular degeneration suppression and LC3B and NF-κB p65 immunopositivity. Conclusion: Olaparib induced ovarian injury accompanied by oxidative stress, cytokine-mediated inflammation, IRE1α-related endoplasmic reticulum stress, cleaved Caspase-3-related apoptosis, LC3B-related autophagy, and NF-κB-related inflammatory signaling. Both ATP and TPP attenuated olaparib-associated injury, with greater effects for ATP. These findings suggest that maintenance of cellular energy homeostasis may represent a promising strategy for attenuating PARP inhibitor-induced ovarian injury. © 2026 Paltaci et al.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Paltaci, Seyma Ilayda | |
| dc.contributor.author | Yilmaz, Nesrin | |
| dc.contributor.author | Kozali Uzun, Sukran | |
| dc.contributor.author | Yavuzer, Bulent | |
| dc.contributor.author | Coban, Taha Abdulkadir | |
| dc.contributor.author | Ozkaraca, Mustafa | |
| dc.contributor.author | Gungor, Ali | |
| dc.contributor.author | Yaqubov, Kamandar | |
| dc.contributor.author | Suleyman, Halis | |
| dc.date.accessioned | 2026-10-18T20:25:52.785233289Z | |
| dc.date.available | 2026-10-18T20:25:52.785233289Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background: Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor used to treat several malignancies. Previous studies have reported that olaparib may induce ovarian injury by elevating reactive oxygen species and impairing cellular energy homeostasis. ATP is a central regulator of intracellular energy balance and antioxidant defense, whereas thiamine pyrophosphate (TPP), the active form of vitamin B1, supports ATP biosynthesis and possesses antioxidant and anti-inflammatory properties. This study compared the protective effects of ATP and TPP against olaparib-induced ovarian injury in rats. Methods: Twenty-four female Wistar albino rats were randomly assigned to four groups (n=6 each): healthy control (HG), olaparib-only (OLP), ATP plus olaparib (ATOL), and TPP plus olaparib (TPOL). Olaparib (100 mg/kg, orally, twice daily), ATP (5 mg/kg, intraperitoneally, once daily), and TPP (25 mg/kg, intraperitoneally, once daily) were administered for 14 consecutive days. Ovarian tissue levels of oxidant (MDA), antioxidants (tGSH, SOD, CAT), and pro-inflammatory cytokine (IL-6) were determined. Tissue specimens underwent histopathological (follicular and parenchymal degeneration) and double immunofluorescence analyses (IRE1α, cleaved Caspase-3, LC3B, and NF-κB p65 immunopositivity). Results: Olaparib significantly increased oxidant and pro-inflammatory cytokine levels and decreased antioxidant levels. Histopathology revealed severe follicular and parenchymal degeneration, and immunofluorescence analysis showed significantly increased IRE1α, cleaved Caspase-3, LC3B, and NF-κB p65 immunopositivity. Both ATP and TPP pre-treatment significantly attenuated olaparib-induced oxidative stress, inflammatory responses, histopathological injury, and cellular stress marker immunopositivity. ATP demonstrated a more pronounced protective effect than TPP, particularly regarding follicular degeneration suppression and LC3B and NF-κB p65 immunopositivity. Conclusion: Olaparib induced ovarian injury accompanied by oxidative stress, cytokine-mediated inflammation, IRE1α-related endoplasmic reticulum stress, cleaved Caspase-3-related apoptosis, LC3B-related autophagy, and NF-κB-related inflammatory signaling. Both ATP and TPP attenuated olaparib-associated injury, with greater effects for ATP. These findings suggest that maintenance of cellular energy homeostasis may represent a promising strategy for attenuating PARP inhibitor-induced ovarian injury. © 2026 Paltaci et al. | |
| dc.identifier.doi | 10.2147/dddt.s634516 | |
| dc.identifier.issn | 1177-8881 | |
| dc.identifier.pmcid | PMC13625991 | |
| dc.identifier.pmid | 42820079 | |
| dc.identifier.scopus | 2-s2.0-105052311187 | |
| dc.identifier.startpage | 634516 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10724 | |
| dc.identifier.volume | 20 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Drug design, development and therapy | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | adenosine triphosphate | |
| dc.subject | apoptosis | |
| dc.subject | autophagy | |
| dc.subject | endoplasmic reticulum stress | |
| dc.subject | inflammation | |
| dc.subject | olaparib | |
| dc.subject | ovarian diseases/chemically induced | |
| dc.subject | oxidative stress | |
| dc.subject | rats | |
| dc.subject | thiamine pyrophosphate | |
| dc.subject | Animals | |
| dc.subject | Caspase 3 | |
| dc.subject | Dose-Response Relationship, Drug | |
| dc.subject | Endoribonucleases | |
| dc.subject | Female | |
| dc.subject | Microtubule-Associated Proteins | |
| dc.subject | Ovary | |
| dc.subject | Phthalazines | |
| dc.subject | Piperazines | |
| dc.subject | Protein Serine-Threonine Kinases | |
| dc.subject | Rats, Wistar | |
| dc.subject | Transcription Factor RelA | |
| dc.subject | microtubule associated protein | |
| dc.subject | phthalazine derivative | |
| dc.subject | piperazine derivative | |
| dc.subject | protein serine threonine kinase | |
| dc.subject | ribonuclease | |
| dc.subject | animal | |
| dc.subject | comparative study | |
| dc.subject | dose response | |
| dc.title | Comparative Protective Effects of ATP and TPP Against Olaparib-Induced Ovarian Injury in Rats: Insights from Biochemical Parameters, Histopathology, and IRE1α, Cleaved Caspase-3, LC3B, and NF-κB p65 Double Immunofluorescence | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 0 | |
| rdl.department | Department of Obstetrics and Gynecology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey. | Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey. | Department of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | PUBMED |
